MedTrace Logo

COVID-2019 Vaccine Immune Response Base on Single Cell Multi-Omics

NCT04871932 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2021-06-03

No results posted yet for this study

Summary

In recent years, single-cell high-throughput sequencing technology has developed rapidly and is widely used in research related to the immune system, breaking traditional cognition and gaining a new understanding of immune cell classification. In particular, the emerging single cell RNA sequencing (scRNA-seq) provides new ideas for the study of cell heterogeneity in multicellular organisms. Analyzing the changes in the expression profile of the cell transcriptome at the single-cell level can clearly show the changes in the trajectory of individual cells, reveal new cell types, and discover the potential functions of immune cells. Therefore, this study intends to recruit healthy adults and use multi-omics techniques such as single-cell sequencing to systematically classify the peripheral blood mononuclear cells of healthy adults to provide a basis for further disease-related research.

Conditions

  • Immune System and Related Disorders

Interventions

BIOLOGICAL

Recently Vaccination

Sponsors & Collaborators

  • RenJi Hospital

    lead OTHER

Principal Investigators

  • Jun Pu, MD,PhD · Cardiology, Ren Ji Hospital Shanghai, China

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-02-01
Primary Completion
2026-11-03
Completion
2026-12-03

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04871932 on ClinicalTrials.gov